D.E. Shaw & Co’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-201,057
| Closed | -$3.91M | – | 4036 |
|
|
2018
Q1 | $3.91M | Sell |
201,057
-339,356
| -63% | -$6.66M | 0.01% | 1570 |
|
|
2017
Q4 | $9M | Sell |
540,413
-317,057
| -37% | -$5.81M | 0.01% | 1096 |
|
|
2017
Q3 | $17.4M | Buy |
857,470
+458,980
| +115% | +$8.77M | 0.03% | 669 |
|
|
2017
Q2 | $6.42M | Buy |
398,490
+344,318
| +636% | +$5.09M | 0.01% | 1160 |
|
|
2017
Q1 | $685K | Sell |
54,172
-5,312
| -9% | -$64.2K | ﹤0.01% | 2561 |
|
|
2016
Q4 | $788K | Sell |
59,484
-36,857
| -38% | -$630K | ﹤0.01% | 2604 |
|
|
2016
Q3 | $2.28M | Buy |
96,341
+38,487
| +67% | +$1.03M | ﹤0.01% | 1830 |
|
|
2016
Q2 | $1.67M | Sell |
57,854
-6,847
| -11% | -$223K | ﹤0.01% | 2059 |
|
|
2016
Q1 | $2.07M | Sell |
64,701
-169,616
| -72% | -$5.96M | ﹤0.01% | 1859 |
|
|
2015
Q4 | $10M | Buy |
234,317
+166,241
| +244% | +$6.64M | 0.01% | 977 |
|
|
2015
Q3 | $2.4M | Sell |
68,076
-63,792
| -48% | -$2.87M | ﹤0.01% | 1956 |
|
|
2015
Q2 | $6.05M | Buy |
131,868
+3,492
| +3% | +$166K | 0.01% | 1330 |
|
|
2015
Q1 | $6.02M | Sell |
128,376
-43,578
| -25% | -$1.73M | 0.01% | 1260 |
|
|
2014
Q4 | $5.45M | Sell |
171,954
-107,362
| -38% | -$3.14M | 0.01% | 1504 |
|
|
2014
Q3 | $6.62M | Buy |
279,316
+65,632
| +31% | +$1.68M | 0.01% | 1376 |
|
|
2014
Q2 | $6.41M | Sell |
213,684
-456,518
| -68% | -$12.3M | 0.01% | 1423 |
|
|
2014
Q1 | $17.7M | Sell |
670,202
-65,597
| -9% | -$1.64M | 0.03% | 713 |
|
|
2013
Q4 | $18.5M | Buy |
735,799
+168,495
| +30% | +$3.76M | 0.03% | 730 |
|
|
2013
Q3 | $11.6M | Buy |
567,304
+119,015
| +27% | +$2.46M | 0.02% | 897 |
|
|
2013
Q2 | $8.94M | Buy |
+448,289
| New | +$7.96M | 0.02% | 935 |
|
D.E. Shaw & Co's IPXL Position: Q2 2018 in Review
D.E. Shaw & Co sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 201,057 shares — an estimated $3.91M sold.
D.E. Shaw & Co first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $18.5M in Q4 2013. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- D.E. Shaw & Co reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- D.E. Shaw & Co sold 201,057 Impax Laboratories, Inc. shares in Q2 2018, an estimated $3.91M.
- D.E. Shaw & Co first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- D.E. Shaw & Co's Impax Laboratories, Inc. position peaked at $18.5M in Q4 2013.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.